We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
FDA批准Vepdegestrant——首个用于ESR1突变乳腺癌的蛋白降解剂片剂。无进展生存期5个月，对比氟维司群的2.1个月。了解为何这是一次范式转变。
